Clinical outcomes in patients evaluated for efficacy: response to treatment
| . | n (%) (N = 17) . | 90% confidence interval . |
|---|---|---|
| ORR | 7 (41.2) | 21.2, 63.6 |
| CR | 2 (11.8) | 12.4, 52.2 |
| Partial response | 5 (29.4) | 2.1, 32.6 |
| Stable disease | 6 (35.3) | 16.6, 58.0 |
| Progressive disease | 3 (17.6) | 5.0, 39.6 |
| No assessment | 1 (5.9)* | 0.3, 25.0 |
| . | n (%) (N = 17) . | 90% confidence interval . |
|---|---|---|
| ORR | 7 (41.2) | 21.2, 63.6 |
| CR | 2 (11.8) | 12.4, 52.2 |
| Partial response | 5 (29.4) | 2.1, 32.6 |
| Stable disease | 6 (35.3) | 16.6, 58.0 |
| Progressive disease | 3 (17.6) | 5.0, 39.6 |
| No assessment | 1 (5.9)* | 0.3, 25.0 |
Patient discontinued pembrolizumab therapy prior to the first radiologic tumor assessment because of clinical disease progression.